Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

Core Insights - Galectin Therapeutics, Inc. announced the presentation of top-line results from the NAVIGATE trial at the 2025 MASH-TAG Conference, focusing on patients with MASH cirrhosis and portal hypertension [1] - The company is also engaging with stakeholders during the JP Morgan Healthcare Conference to discuss the NAVIGATE trial results and the belapectin program [1] Company Overview - Galectin Therapeutics is focused on developing therapies for chronic liver disease and cancer, with its lead drug belapectin targeting the galectin-3 protein, which is involved in inflammatory and fibrotic diseases [2] - Belapectin has received Fast Track designation from the U.S. FDA and is primarily aimed at treating metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis, representing a significant medical need and drug development opportunity [2] - The company is also exploring additional development programs for combination immunotherapy in advanced head and neck cancers and other malignancies, contingent on finding suitable partnerships [2]